Friday, August 28, 2026
← Back to archivePolicy
Policy•Endpoints News•Aug 27, 2026
Roivant's dermatomyositis drug Lisraya snags FDA approval
background ▾
- •First FDA approval for brepocitinib and first JAK inhibitor approved for dermatomyositis, establishing a new standard of care in a rare disease with high unmet medical need
- •Represents a critical validation of Roivant's asset development strategy and could unlock multibillion-dollar revenue potential, strengthening the company's pipeline and financial position
- •Market uptake will hinge on reimbursement coverage, JAK inhibitor safety considerations, and physician adoption in dermatology/rheumatology—watch for payer coverage determinations and real-world usage data
RoivantbrepocitinibLisraya
→ Read original articlePolicy•STAT News•Aug 28, 2026
Opinion: We quit the CDC last year. The problems we protested remain
background ▾
- •CDC's scientific integrity has been undermined through politicization of previously career-level positions and suppression of peer-reviewed findings on vaccine efficacy and public health interventions.
- •The first-ever moratorium on the CDC's 60-year-old Morbidity and Mortality Weekly Report occurred in early 2025 when acting director Jay Bhattacharya rejected publication of research demonstrating Covid vaccine effectiveness, though the paper later passed peer review in JAMA.
- •Congress is being urged to establish statutory firewalls protecting CDC scientific publications from political interference, requiring transparent documentation of any decisions to delay, alter, or block reports.
Policy•STAT News•Aug 28, 2026
Opinion: A billing code was supposed to incentivize relationship-based primary care for Medicare patients. It may not be working as hoped
background ▾
- •G2211 code achieved 26 million billings in first year with 1 in 4 Medicare-billing physicians using it, but usage patterns deviate from intended design with specialists capturing 43% of billings versus 40% for primary care physicians
- •The $16 per-visit add-on may be too modest to fundamentally change the fee-for-service incentive structure that drives specialists and primary care clinicians toward higher visit volumes rather than relationship-based, between-visit care activities
- •Monitor whether CMS will modify G2211 billing criteria, increase reimbursement rates, or pursue alternative payment models (capitation, shared savings) to more effectively redirect financial incentives toward primary care and longitudinal patient relationships
Policy•Endpoints News•Aug 27, 2026
Gilead gets another HIV treatment approval, extending lenacapavir's dominance
background ▾
- •Lenacapavir receives expanded FDA approval, indicating sustained regulatory confidence in the drug's safety and efficacy profile
- •Approval reinforces Gilead's entrenched leadership in HIV treatment and protects market share against emerging competitors
- •Payer adoption velocity and real-world clinical utilization patterns will determine commercial impact in an increasingly competitive HIV space
Gilead Scienceslenacapavir
→ Read original articlePolicy•KFF•Aug 27, 2026
Examining LGBTQ+ Adults’ Experiences with Health Care Costs and Access
background ▾
- •LGBTQ+ adults are nearly twice as likely as non-LGBTQ+ adults to delay or forgo needed care due to cost (43% vs. 26%), with transgender adults experiencing the highest burden at 56% delaying care for financial reasons.
- •Health care affordability and access gaps in the LGBTQ+ population are substantial and multifactorial, driven by cost barriers, provider availability, and discrimination—particularly acute for transgender adults who face 82% delayed care rates.
- •This data may inform future health policy, payer coverage decisions, and pharmaceutical company market access strategies targeting underserved populations, though the direct commercial implications for individual drug products remain unclear.
Market Access
Market Access•Fierce Biotech•Aug 27, 2026
Roche nabs expanded FDA approval for diagnostic tied to Jazz’s cancer drug
background ▾
- •Roche's diagnostic tests now enable HER2 patient stratification across three gastroesophageal cancer subtypes (gastric, GEJ, and esophageal), filling a previous diagnostic void for esophageal adenocarcinoma
- •This diagnostic approval directly supports Jazz's Ziihera label expansion into first-line GEA, creating a companion diagnostic linkage that facilitates market penetration in aggressive cancers typically diagnosed at late stages
- •Monitor Ziihera uptake in GEA and whether diagnostic-drug bundling strategies emerge in gastric/esophageal cancer, plus any competitive HER2-targeting approaches in this indication
RocheJazz PharmaceuticalsZiihera
→ Read original articleMarket Access•Fierce Biotech•Aug 28, 2026
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
background ▾
- •Genentech's $1B+ deal validates Dupac as a clinically meaningful solution for the ADC-resistance problem emerging as topoisomerase-based ADCs move into earlier treatment lines
- •DualityBio's platform has demonstrated preclinical efficacy advantages over current standards (Blenrep, DS-3939a) and represents a differentiated approach to overcome ADC resistance
- •Monitor DualityBio's 2025 regulatory filing for TA-MUC1 ADC and subsequent clinical readouts; track Genentech's phase 1a data and advancement timelines, as this will determine whether Dupac payloads translate to clinical benefit in resistant disease
RocheGenentechDualityBioEnhertuTrodelvyBlenrep
→ Read original articleMarket Access•Fierce Biotech•Aug 27, 2026
After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platform
background ▾
- •Frontier claims to have identified small-molecule chemical matter targeting 8,000 human proteins, more than historical industry capacity, providing optionality for previously undruggable cancer targets
- •Recent layoffs and restructuring reflect broader biotech funding headwinds; CEO frames 2025 as recovery year with advancing clinical programs as proof of platform utility
- •Key execution risk: transition from chemoproteomics data generation to successful clinical candidates remains unproven; no specific drug names, trial timelines, or partnership details disclosed in announcement
Frontier MedicinesBlueprint MedicinesSanofi
→ Read original articleMarket Access•Endpoints News•Aug 27, 2026
Lilly's move to hide Phase 1 pipeline draws mixed reviews
background ▾
- •Eli Lilly is reducing public disclosure of Phase 1 pipeline programs, prioritizing focus on its high-value late-stage and commercial assets
- •This strategic communication shift occurs amid the company's record-breaking GLP-1 performance and dominant market capitalization in healthcare
Eli LillyGLP-1 receptor agonist (class)
→ Read original articleMarket Access•Endpoints News•Aug 27, 2026
Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins
background ▾
- •Moderna raised $2 billion via convertible notes offering, indicating capital market access and financial planning flexibility
- •AstraZeneca-Amgen and Biokin achieved Phase 3 trial victories, though specific drug names and therapeutic areas are not disclosed in available text
ModernaAstraZenecaAmgen
→ Read original articleClinical Trials
Clinical Trials•STAT News•Aug 27, 2026
What’s in Merck and Moderna’s cancer vaccine algorithm?
background ▾
- •Moderna-Merck cancer vaccine could be the first approved drug powered by a proprietary neoantigen-selection algorithm, representing a novel regulatory and computational paradigm in personalized medicine.
- •Rasonque's FDA approval for KRAS-driven pancreatic cancer doubles median survival (13.2 vs. 6.7 months) and establishes a new standard of care for a disease with dismal prognosis, opening potential expansion to other RAS-driven malignancies.
- •Rival gene-silencing drug eplontersen's Phase 3 failure raises questions about the clinical utility of injectable RNAi therapies in ATTR-CM when combined with oral stabilizers, posing uncertainty for Alnylam's nucresiran program and broader gene-silencing asset class.
ModernaMerckRevolution MedicinesRasonqueKeytrudaAmvuttra
→ Read original articleClinical Trials•Endpoints News•Aug 28, 2026
#ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approval
background ▾
- •Myqorzo Phase 3 data supports expanded indication with potential to double market reach
- •Regulatory filing expected in 2025, suggesting near-term label expansion opportunity
- •Precise indication and comparator efficacy data not detailed in available text
CytokineticsMyqorzoomecamtiv mecarbil
→ Read original articleClinical Trials•Endpoints News•Aug 28, 2026
#ESC26: Trial failure clouds future of AstraZeneca’s heart disease gene silencer
background ▾
- •Wainua failed its primary trial endpoint, with apparent drug-drug interactions or medication confounders identified as a contributing factor to the failure.
- •This represents a major setback for AstraZeneca's gene silencing cardiovascular pipeline and raises questions about Ionis's antisense platform in this indication.
- •Watch for: full trial readout at ESC and subsequent investor calls, potential strategic pivots for both companies, and impact on other Ionis-partnered programs in cardiovascular disease.
AstraZenecaIonis PharmaceuticalsWainua
→ Read original articleClinical Trials•Fierce Biotech•Aug 27, 2026
Research into protein interactions sheds new light on causes of autism
background ▾
- •UCSF mapped 1,800 protein interactions from autism risk genes, with 87% novel—identifying FOXP1-FOXP4 as a validated therapeutic target where FOXP4 inhibition rescues autism-like phenotypes in organoid models
- •AlphaFold-enabled structural prediction enabled researchers to distinguish direct protein interactions from indirect associations, solving a major bottleneck in protein-centric drug discovery
- •Krogan's startup plans and pharma partnerships signal potential commercialization of this protein-interaction platform; monitor for company formation and early collaboration announcements in autism/neurology drug discovery
University of California, San FranciscoGoogle DeepMindInsilico MedicineFOXP1FOXP4
→ Read original articleClinical Trials•Fierce Biotech•Aug 27, 2026
With mRNA back in the spotlight, tRNA shows potential to treat genetic disease
background ▾
- •Modified inhalable tRNA demonstrated safety and efficacy in restoring CFTR protein function in cystic fibrosis models, with 40-day lung tissue persistence—substantially longer than mRNA therapies.
- •Synergistic effect observed when tRNA combined with approved Trikafta in CF patient cells, suggesting potential for combination therapy strategies.
- •Clinical translation expected within 2-3 years; ongoing preclinical testing in DMD and Rett syndrome indicates broader pipeline potential for nonsense mutation-driven genetic diseases.
University of TorontoVertex PharmaceuticalsModernatRNA (modified, inhalable)TrikaftaKeytruda
→ Read original article